(A) Dose range study at baseline
Expert insight from our panelists: Morgan Lee, PhD, MPH, CPH Vice President, Research & Marketing Scott Halperin, PharmD Vice President, Employer Pharmacy Benefit Consulting Steve Altenburger, PharmD Senior Pharmacy Benefit Consultant
This action starts a key process called the cyclic adenosine monophosphate (cAMP) pathway, essential for making melanin
Orforglipron: First Oral GLP-1 Without Refrigeration Eli Lillys Orforglipron is a once-daily GLP-1 receptor agonist currently in advanced clinical trials
What it means for you If you have diabetes or obesity and are prescribed a GLP-1 RA anyway, it may be a potential added brain-health benefitbut not a guarantee
1 Introduction Despite decades of intensive research and substantial investmentwith Alzheimers disease alone projected to surpass 1 trillion USD in global cost by 2050 (Nandi et al., 2024), therapeutic progress in neurodegenerative disorders has remained limited, with most clinical approaches continuing to target downstream proteinopathies and yielding only modest effects on disease trajectories (Selkoe and Hardy, 2016
